Alphatec Holdings, Inc. (ATEC) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This summary covers Alphatec Holdings, Inc.'s unaudited financial results for the quarter ended March 31, 2026. Alphatec is a medical technology company focused on spinal disorders, operating through subsidiaries Alphatec Spine, SafeOp Surgical, and EOS imaging. The company markets spinal implants and imaging equipment globally via direct sales and independent agents.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $192.1 million | $169.2 million |
| Gross Profit | $136.5 million | $116.0 million |
| Gross Margin | 71.0% | 68.6% |
| Operating Loss | $(22.6) million | $(44.3) million |
| Net Loss | $(33.9) million | $(51.9) million |
| Diluted EPS | $(0.22) | $(0.35) |
| Cash from Operations | $1.3 million | $(5.0) million |
| Cash & Equivalents (End of Period) | $139.9 million | $153.2 million |
| Total Debt (Principal) | $692.4 million | N/A |
Note: Total debt principal includes $63.3M in 2026 Notes, $200M in Braidwell Term Loan, $15.1M in Revolver, and $405M in 2030 Notes.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 14% ($22.9M) driven by higher product volume, an expanded surgeon user base, and new product adoption.
- Expense Reduction: Litigation-related expenses dropped 96% to $0.5M from $12.2M in Q1 2025, following a settlement in the prior year. Restructuring expenses were eliminated ($0 vs $0.4M).
- Operating Expenses: SG&A increased 8% ($10.0M) due to higher compensation and variable selling costs tied to revenue growth. R&D increased 6% ($1.0M) primarily due to compensation.
- Interest Expense: Net interest expense rose 49% to $11.7M, largely due to amortization of debt discounts on the 2030 Notes issued in March 2025.
- Balance Sheet: Stockholders' equity moved from a positive $12.4M at year-end 2025 to a deficit of $(5.3)M due to the Q1 net loss.
Outlook, Risks, and Unusual Items
- Subsequent Financing Event: On May 1, 2026, the company entered a new credit agreement with JP Morgan Chase for a $175M term loan and $125M revolver. Proceeds were used to fully repay the existing Braidwell Term Loan and Revolving Credit Facility.
- Debt Maturities: The 2026 Convertible Notes ($63.3M principal) mature in August 2026. Holders may convert notes if stock price conditions are met.
- Liquidity: Management believes existing cash, operations, and financing access are adequate for working capital and debt service. However, the company maintains a significant debt load with interest rates tied to SOFR plus spreads.
- Risks: Key risks include the ability to achieve profitability, regulatory compliance (FDA), litigation outcomes, and foreign currency exposure as international revenue grows (currently ~6% of total revenue).
Investor Verification Checklist
- Verify the terms and interest rates of the new May 1, 2026, JP Morgan credit facility replacing the Braidwell debt.
- Monitor the conversion status and potential dilution of the $63.3M 2026 Notes maturing in August 2026.
- Assess the sustainability of the 14% revenue growth rate against the continued high SG&A expense base.
- Review the status of the NuVasive litigation (noted as terminated in Q1 2026) for any residual financial impacts.
- Confirm inventory levels ($186M) relative to sales velocity to evaluate obsolescence risks.